Iobenguane

BreastfeedingPediatric
  • TRADE NAME: AdreView (GE Healthcare)
  • INDICATIONS: Detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests
  • SYNONYM: metaiodobenzylguanidine; MIBG
  • CLASS: Radiopharmaceutical, diagnostic agent
  • HALF-LIFE: 13 hours

Our database has 18 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
HEMATOLOGIC.
LOCAL.
RESPIRATORY.
OTHER.


Page last updated 08/01/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top